Table 4.
Outcomes of transfemoral vs. transapical access
| Outcomes | Transfemoral | Transapical | P ** | ||||
|---|---|---|---|---|---|---|---|
| ES (95% CI) | I 2 (%) | P * | ES (95% CI) | I 2 (%) | P * | ||
| 30 day procedural outcomes | |||||||
| Device success | 0.925 (0.875–0.964) | 35.6 | 0.144 | 0.961 (0.939–0.979) | 50.4 | 0.003 | 0.000 |
| Permanent pacemaker implantation | 0.194 (0.148–0.244) | 0.0 | 0.814 | 0.060 (0.043–0.078) | 0.0 | 0.787 | 0.000 |
| Greater‐than‐mild PVL | 0.034 (0.012–0.063) | 0.0 | 0.791 | 0.008 (0.001–0.018) | 0.0 | 0.960 | 0.002 |
| Mild PVL | 0.184 (0.115–0.263) | 29.5 | 0.235 | 0.216 (0.117–0.259) | 13.1 | 0.314 | 0.314 |
| No/trace PVL | 0.781 (0.685–0.866) | 42.9 | 0.154 | 0.769 (0.683–0.846) | 76.2 | 0.000 | 0.897 |
| 30 day clinical outcomes | |||||||
| 30 day mortality | 0.040 (0.012–0.078) | 28.9 | 0.208 | 0.029 (0.014–0.047) | 30.7 | 0.117 | 0.052 |
CI, confidence interval; ES, effect size; I 2, the variation attributable to heterogeneity; PVL, paravalvular leak.
*
P value for significance of I 2.
**
P value for significance of the χ 2 or Fisher's exact test.